263 related articles for article (PubMed ID: 22013048)
1. p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes.
Mesplède T; Gagnon D; Bergeron-Labrecque F; Azar I; Sénéchal H; Coutlée F; Archambault J
J Virol; 2012 Jan; 86(1):94-107. PubMed ID: 22013048
[TBL] [Abstract][Full Text] [Related]
2. Degradation of p53 by human Alphapapillomavirus E6 proteins shows a stronger correlation with phylogeny than oncogenicity.
Fu L; Van Doorslaer K; Chen Z; Ristriani T; Masson M; Travé G; Burk RD
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20862247
[TBL] [Abstract][Full Text] [Related]
3. Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6.
Wang H; Mo P; Ren S; Yan C
J Biol Chem; 2010 Apr; 285(17):13201-10. PubMed ID: 20167600
[TBL] [Abstract][Full Text] [Related]
4. A high-throughput cellular assay to quantify the p53-degradation activity of E6 from different human papillomavirus types.
Gagnon D; Archambault J
Methods Mol Biol; 2015; 1249():111-20. PubMed ID: 25348301
[TBL] [Abstract][Full Text] [Related]
5. Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.
Kehmeier E; Rühl H; Voland B; Stöppler MC; Androphy E; Stöppler H
Virology; 2002 Jul; 299(1):72-87. PubMed ID: 12167343
[TBL] [Abstract][Full Text] [Related]
6. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification.
Hiller T; Poppelreuther S; Stubenrauch F; Iftner T
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1262-7. PubMed ID: 16835321
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of transforming properties of E6 and E7 from different beta human papillomavirus types.
Cornet I; Bouvard V; Campo MS; Thomas M; Banks L; Gissmann L; Lamartine J; Sylla BS; Accardi R; Tommasino M
J Virol; 2012 Feb; 86(4):2366-70. PubMed ID: 22171257
[TBL] [Abstract][Full Text] [Related]
9. Degradation of Human PDZ-Proteins by Human Alphapapillomaviruses Represents an Evolutionary Adaptation to a Novel Cellular Niche.
Van Doorslaer K; DeSalle R; Einstein MH; Burk RD
PLoS Pathog; 2015 Jun; 11(6):e1004980. PubMed ID: 26086730
[TBL] [Abstract][Full Text] [Related]
10. Isolation and functional analysis of five HPVE6 variants with respect to p53 degradation.
Hiller T; Stubenrauch F; Iftner T
J Med Virol; 2008 Mar; 80(3):478-83. PubMed ID: 18205217
[TBL] [Abstract][Full Text] [Related]
11. Degradation of p53 by HPV16-E6 variants isolated from cervical cancer specimens of Moroccan women.
Hadami K; Saby C; Dakka N; Collin G; Attaleb M; Khyatti M; Filali-Maltouf A; Morjani H; El Mzibri M
Gene; 2021 Jul; 791():145709. PubMed ID: 33984442
[TBL] [Abstract][Full Text] [Related]
12. Roles for E1-independent replication and E6-mediated p53 degradation during low-risk and high-risk human papillomavirus genome maintenance.
Murakami I; Egawa N; Griffin H; Yin W; Kranjec C; Nakahara T; Kiyono T; Doorbar J
PLoS Pathog; 2019 May; 15(5):e1007755. PubMed ID: 31083694
[TBL] [Abstract][Full Text] [Related]
13. Phylogenetic and functional analysis of sequence variation of human papillomavirus type 31 E6 and E7 oncoproteins.
Ferenczi A; Gyöngyösi E; Szalmás A; László B; Kónya J; Veress G
Infect Genet Evol; 2016 Sep; 43():94-100. PubMed ID: 27197052
[TBL] [Abstract][Full Text] [Related]
14. Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.
Conrady MC; Suarez I; Gogl G; Frecot DI; Bonhoure A; Kostmann C; Cousido-Siah A; Mitschler A; Lim J; Masson M; Iftner T; Stubenrauch F; Travé G; Simon C
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115863
[TBL] [Abstract][Full Text] [Related]
15. Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.
Stutz C; Reinz E; Honegger A; Bulkescher J; Schweizer J; Zanier K; Travé G; Lohrey C; Hoppe-Seyler K; Hoppe-Seyler F
PLoS One; 2015; 10(7):e0132339. PubMed ID: 26151636
[TBL] [Abstract][Full Text] [Related]
16. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro.
Slebos RJ; Kessis TD; Chen AW; Han SM; Hedrick L; Cho KR
Virology; 1995 Apr; 208(1):111-20. PubMed ID: 11831691
[TBL] [Abstract][Full Text] [Related]
17. Association of p53 codon 72 genotypes and clinical outcome in human papillomavirus-infected lung cancer patients.
Chen SP; Hsu NY; Wu JY; Chen CY; Chou MC; Lee H; Cheng YW
Ann Thorac Surg; 2013 Apr; 95(4):1196-203. PubMed ID: 23522190
[TBL] [Abstract][Full Text] [Related]
18. Star-PAP controls HPV E6 regulation of p53 and sensitizes cells to VP-16.
Li W; Anderson RA
Oncogene; 2014 Feb; 33(7):928-32. PubMed ID: 23416977
[TBL] [Abstract][Full Text] [Related]
19. Identification of MicroRNAs That Stabilize p53 in Human Papillomavirus-Positive Cancer Cells.
Martínez-Noël G; Szajner P; Kramer RE; Boyland KA; Sheikh A; Smith JA; Howley PM
J Virol; 2022 Feb; 96(4):e0186521. PubMed ID: 34878887
[TBL] [Abstract][Full Text] [Related]
20. E6 proteins from high-risk HPV, low-risk HPV, and animal papillomaviruses activate the Wnt/β-catenin pathway through E6AP-dependent degradation of NHERF1.
Drews CM; Case S; Vande Pol SB
PLoS Pathog; 2019 Apr; 15(4):e1007575. PubMed ID: 31002735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
